To accelerate COVID-19 vaccine development and boost vaccine manufacturing capacity within its borders, the German Federal Ministry of Education and Research is awarding BioNTech (NASDAQ: BNTX) and CureVac N.V. (NASDAQ: CVAC) grants worth up to $743 million at current euro-to-U.S. dollar conversion rates.
Specifically, BioNTech can receive up to 375 million euros, or $444 million, to advance its BNT162 vaccine program in collaboration with Pfizer (NYSE: PFE), and CureVac can pocket up to 252 million euros, or $299 million, to continue development of its COVID-19 vaccine program.
IMAGE SOURCE: GETTY IMAGES.
Currently, BioNTech and Pfizer are conducting phase 3 trials of BNT162b2 with preliminary results expected in October. If the trial is successful, then the healthcare companies plan to submit applications to regulators for its emergency use. CureVac's COVID-19 program is in phase 1 trials, and data that could allow it to enter phase 3 trials is expected in the fourth quarter.
Previously, BioNTech and Pfizer agreed to provide up to 200 million doses of its vaccine to the European Union beginning later this year if the vaccine wins a regulatory green light. Separately, CureVac says its negotiating with the European Commission to provide up to 225 million doses, plus an option for up to an additional 180 million doses.
The grants are contingent upon the companies achieving development milestones. According to BioNTech, it has already met five of eight requirements. CureVac anticipates receiving 103 million euros in 2020 and up to 149 million euros in 2021, depending on its successfully meeting its goals.
10 stocks we like better than BioNTech SE
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and BioNTech SE wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 1, 2020
Todd Campbell owns shares of Pfizer. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.